Tag: Nimotuzumab
Nimotuzumab boosts survival rates in head & neck cancer: Tata Memorial...
Phase III study shows significant improvement in 10-year survival rates with Nimotuzumab addition, offering new hope for patients
Biocon’s indigenous biologic for head & neck cancer a viable solution,...
At a panel discussion held by the Biocon at New Delhi, the leading oncologists deliberated on the results of a large scale clinical study on novel biologic, BioMab EGFR (Nimotuzumab) for head and neck cancer and its impact as a targeted therapy on patient outcomes